Penetration of piperacillin and tazobactam into pneumonic human lung tissue measured by in vivo microdialysis

British Journal of Clinical Pharmacology

Volumn 55, Issue 6, 2003, Pages 620-624

  Tomaselli, Florian ^a   Dittrich, Peter ^b   Maier, Alfred ^a   Woltsche, Michael ^b   Matzi, Veronika ^a   Pinter, Johannes ^a   Nuhsbaumer, Stephan ^a   Pinter, Hans ^a   Smolle, Josef ^b   Smolle Jüttner, Freyja M ^a  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

^b UNIVERSITY OF GRAZ   (Austria)

Author keywords

Human lung; In vivo; Microdialysis; Pharmacokinetics; Piperacillin; Target site; Tazobactam

Indexed keywords

PIPERACILLIN PLUS TAZOBACTAM; TAZONAM;

ADULT; AGED; ANTIBIOTIC THERAPY; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG PENETRATION; DRUG TISSUE LEVEL; FEMALE; HUMAN; LUNG PARENCHYMA; MALE; PLEURA EMPYEMA; PNEUMONIA; PRIORITY JOURNAL; SEPSIS; THORACOTOMY;

ADULT; AGED; AREA UNDER CURVE; ENZYME INHIBITORS; FEMALE; HUMANS; LUNG; MALE; MICRODIALYSIS; MIDDLE AGED; PENICILLANIC ACID; PENICILLINS; PIPERACILLIN; PNEUMONIA; SEPSIS;

EID: 0037789570     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.2003.01797.x     Document Type: Article

References (37)

1. Chesnutt MS, Prendergast TJ. Pulmonary infections. In Current Medical Diagnosis and Treatment, eds Tierny LW, McPhee SJ, Papadakis MA, New York: Lange Medical Publishing/McGraw-Hill, 2001: 291-300.
2. Joukhadar C, Derendorf H, Müller M. Microdialysis, a novel tool for clinical studies of anti-infective agents. Eur J Clin Pharmacol, DOI 10.1007/s002280100301 Article in HTML, published online at: http://link.springer.de/link/service/journals/00228/contents/01/00301/ 8 May 2001.
3. Hyatt JM, McKinnon PS, Zimmer GS, Schentag JJ. The importance of pharmacokinetic/pharmacodynamic surrogate markers to outcome. Focus on antibacterial agents. Clin Pharmacokinet 1995; 28: 143-160.
4. Bergogne-Berezin E. Penetration of antibiotics into the respiratory tree. J Antimicrob Chemother 1981; 8: 171-174.
5. Drusano GL. Role of pharmacokinetics in the outcome of infections. Antimicrob Agents Chemother 1988; 32: 289-297.
6. Pennington JE. Penetration of antibiotic into respiratory secretions. Rev Infect Dis 1981; 3: 67-73.
7. Jehl F, Muller-Serieys C, de Larminat V, Monteil H, Bergogne-Berezin E. Penetration of piperacillin-tazobactam into bronchial secretions after multiple doses to intensive care patients. Antimicrobial Agents Chemother 1994; 38: 2780-2784.
8. Honeybourne D, Andrews JM, Ashby JP, Lodwick R, Wise R. Evaluation of the penetration of ciprofloxacin and amoxycillin into the bronchial mucosa. Thorax 1988; 43: 715-719.
9. Schentag JJ. Clinical significance of antibiotic tissue penetration. Clin Pharmacokinet 1989; 16 (Suppl. 1): 25-31.
10. The BAL Cooperative Group Steering Committee. Bronchoalveolar lavage constituents in healthy individuals, idiopathic pulmonary fibrosis, and selected comparison groups. Am Rev Respir Dis 1990; 141: S166-S202.
11. Baldwin DR, Honeybourne D, Wise R. Pulmonary disposition of antimicrobial agents: methodological considerations. Antimicrob Agent Chemother 1992; 36: 1171-1175.
12. Hand WL, King-Thompson NL, Steinberg TH. Interactions of antibiotics and phagocytes. J Antimicrob Chemother 1983; 12 (Suppl. C): 1-11.
13. Harf R, Panteix G, Desnottes F, Diallo N, Leciereq M. Spiramycin uptake by alveolar macrophages. J Antimicrob Chemother 1988; 22 (Suppl. B): 135-140.
14. Le Conte P, Potel G, Peltier P et al. Lung distribution and pharmacokinetics of aerosolized tobramycin. Am Rev Respir Dis 1993; 147: 1279-1282.
15. Wollmer P, Pride NB, Rhodes CG et al. Measurement of pulmonary erythromycin concentration in patients with lobar pneumonia by means of positron tomography. Lancet 1982; 2: 1361-1364.
16. Ali I, Unruh H. Management of empyema thoracis. Ann Thor Surg 1990; 55: 355-359.
17. Renner H, Gabor S, Pinter H, Maier A, Friehs G, Smolle-Jüttner FM. Is aggressive surgery in pleural empyema justified? Eur J Cardiothorac Surg 1998; 14: 117-122.
18. Maier A, Domej W, Anegg U et al. CT or ultrasonically guided pigtail catheter drainage in multiloculated pleural empyema: a recommended procedure? Respirology 2000; 5: 119-124.
19. Müller M, Haag O, Burgdorff T et al. Characterization of peripheral-compartment kinetics of antibiotics by in vivo microdialysis in humans. Antimicrob Agents Chemother 1996; 40: 2703-2709.
20. Ståhle L, Arner P, Ungerstedt U. Drug distribution studies with microdialysis III. Extracellular concentration of caffeine in adipose tissue in man. Life Sci 1991; 49: 1853-1858.
21. Wang Y, Wong SL, Sawchuk RJ. Microdialysis calibration using retrodialysis zeronet flux: application to a study of the distribution of zidovudine to rabbit cerebrospinal fluid and thalamus. Pharm Res 1993; 10: 1411-1419.
22. Perry CM, Morkham A. Piperacillin/tazobactam: an updated review of its use in the treatment of bacterial infections. Drugs 1999; 57: 805-843.
23. Mouton Y, Leroy O, Beuscart C. Efficacy, safety and tolerance of parenteral piperacillin/tazobactam in the treatment of patients with lower respiratory tract infections. J Antimicrob Chemother 1993; 31 (Suppl. A): 87-95.
24. Sanders CV Jr. Piperacillin/tazobactam in the treatment of community-acquired and nosocomial respiratory tract infections: a review. Intensive Care Med 1994; 20: 21-26.
25. Smith DL. Parenteral piperacillin/tazobactam with amikacin for the treatment of severe pulmonary infections in intensive care units. Infect Dis Clin Pract 1995; 4 (Suppl. 1): 33-36.
26. Ocampo AP, Hoyt KD, Wadgaonkar N, Carver AH, Puglisi CV. Determination of tazobactam and piperacillin in human serum, serum, bile and urine by gradient elution reversed-phase high-performance liquid chromatography. J Chromatogr Biomed Applications 1989; 496: 167-179.
27. Kinetica 2000, Version 3. Philadelphia, PA: InnaPhase Corp., 2000.
28. Stahle L. Pharmacokmetic estimations from microdialysis data. Eur J Clin Pharmacol 1992; 43: 289-294.
29. Lönnroth P, Jansson PA, Smith U. A microdialysis method allowing characterization of intercellular water space in humans. Am J Physiol 1987; 253: E228-E231.
30. Müller M, Schmid R, Georgopoulos A, Buxbaum A, Wasicek C, Eichler HG. Application of microdialysis to clinical pharmacokinetics in humans. Clin Pharmacol Ther 1995; 57: 371-380.
31. Ryan DM. Pharmacokinetics of antibiotics in natural and experimental superficial compartments in animals and humans. J Antimicrob Chemother 1993; 31 (Suppl. D): 1-16.
32. FDA. Guidance for Industry. Developing Antimicrobial Drugs - General Considerations for Clinical Trials. Published at: http://www.fda.gov/cder/guidance/2580dft.pdf
33. The European Agency for the Evaluation of Medicinal Products. Evaluation of Medicines for Human Use. Points to Consider on Pharmacokinetics and Pharmacodynamics in the Development of Antibacterial Medicinal Products. London: CPMP/EWP/2655/99 Committee for Proprietary Medicinal Products (CPMP). Published electronically at: http://www.emea.eu.int/pdfs/human/ewp/265599en.pdf
34. Department of Health and Human Service, Food and Drug Administration. Guidance Documents on Developing Antimicrobial Drugs. Anti-infective drugs advisory committee meeting, 64th meeting. Washington, DC: Miller Reporting Co., Inc., 1989; 496: 167-179.
35. Honeybourne D, Baldwin DR. The site concentrations of antimicrobial agents in the lung. J Antimicrob Chemother 1992; 30: 249-260.
36. Perry CM, Markham A. Piperacillin/Tazobactam: an updated review of its use in the treatment of bacterial infections. Drugs 1999; 57: 805-843.
37. Müller M, Rohde B, Kovar A. Georgopoulos A, Eichler HG, Derendorf H. Relationship between serum and free interstitial concentrations of Cefodizime and Cefpirome in muscle and subcutaneous adipose tissue of healthy volunteers measured by microdialysis. J Clin Pharmacol 1997; 37: 1008-1113.